OxFORD Asset Management LLP Has $2.09 Million Holdings in Meridian Bioscience Inc. (VIVO)
OxFORD Asset Management LLP raised its position in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 71.1% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 132,656 shares of the company’s stock after purchasing an additional 55,110 shares during the quarter. OxFORD Asset Management LLP owned 0.31% of Meridian Bioscience worth $2,089,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. increased its stake in Meridian Bioscience by 0.7% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 13,091 shares of the company’s stock valued at $206,000 after purchasing an additional 92 shares in the last quarter. Arizona State Retirement System increased its stake in Meridian Bioscience by 0.5% during the 2nd quarter. Arizona State Retirement System now owns 22,041 shares of the company’s stock valued at $347,000 after purchasing an additional 100 shares in the last quarter. Texas Permanent School Fund increased its stake in Meridian Bioscience by 0.8% during the 2nd quarter. Texas Permanent School Fund now owns 30,813 shares of the company’s stock valued at $485,000 after purchasing an additional 258 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in Meridian Bioscience by 3.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock valued at $157,000 after purchasing an additional 370 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in Meridian Bioscience by 0.5% during the 2nd quarter. PNC Financial Services Group Inc. now owns 103,882 shares of the company’s stock valued at $1,635,000 after purchasing an additional 485 shares in the last quarter. Institutional investors and hedge funds own 87.27% of the company’s stock.
In related news, Chairman John A. Kraeutler acquired 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was purchased at an average cost of $13.67 per share, with a total value of $95,690.00. Following the transaction, the chairman now directly owns 345,230 shares of the company’s stock, valued at approximately $4,719,294.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.30% of the company’s stock.
Shares of Meridian Bioscience Inc. (VIVO) opened at 14.70 on Friday. The stock has a 50 day moving average of $14.06 and a 200-day moving average of $14.28. The company has a market capitalization of $620.38 million, a price-to-earnings ratio of 29.40 and a beta of 0.84. Meridian Bioscience Inc. has a 52 week low of $10.75 and a 52 week high of $19.75.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.16 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. The firm had revenue of $50.14 million during the quarter, compared to analyst estimates of $49.13 million. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. Meridian Bioscience’s revenue was down 1.0% on a year-over-year basis. During the same period last year, the firm posted $0.21 EPS. On average, analysts anticipate that Meridian Bioscience Inc. will post $0.67 EPS for the current year.
A number of research firms have weighed in on VIVO. Zacks Investment Research upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday. BidaskClub lowered shares of Meridian Bioscience from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. Meridian Bioscience currently has a consensus rating of “Hold” and a consensus target price of $14.33.
Meridian Bioscience Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.